July 24th 2024
The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.
February 12th 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Health Insurance Coverage Has Little Effect on Childhood Cancer Survival
September 17th 2017Children covered by Medicaid when diagnosed with cancer have similar survival rates compared with children with private insurance, according to a new study. Evidence shows a slightly increased risk of cancer death among uninsured children, which may be related to a more advanced stage at diagnosis.
FDA Approves First Gene Therapy for Pediatric Leukemia
September 1st 2017The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Reduced, Compressed Chemotherapy Fails in Pediatric Germ Cell Tumors
March 11th 2017Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.
Musculoskeletal Manifestations of Pediatric ALL Delayed Diagnosis
January 13th 2017Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.
Genetic Susceptibility to Leukemia in Pediatrics
December 2nd 2016As part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.